Selcan Demir, Seza Özen, Erdal Sağ, Yelda Bilginer, Fatma Bal, Berna Uzunoğlu, Hafize Emine Sönmez

Systemic onset juvenile idiopathic arthritis: a single center experience

Systemic juvenile idiopathic arthritis (sJIA) presents with prolongedfever and systemic features such as arthritis, rash, lymphadenopathy,hepatosplenomegaly and serositis. In this study, we aimed to evaluate theclinical and laboratory findings, and outcomes of sJIA patients from a tertiaryrheumatology center.Between 2010-2017, patients who had been diagnosed with sJIA, participatedin the study. The demographics, clinical and laboratory features, and outcomes,were evaluated retrospectively.Seventy-five sJIA (%56 male) patients were enrolled. The mean age at diagnosiswas 6,45±4,80 years. At the time of diagnosis, the most common findings werefever (%100) followed by arthritis (78,7%), and rash (66,2%). Twenty-fourpercent of the patients present with macrophage activation syndrome (MAS)at the time of diagnosis. Totally, 36% of the patients had at least one MASattack during the course of the disease. 46% of the patients had polyphasiccourse while 54% had one attack (26% monophasic, 28% persistant). All ofthe patients were treated with non-steroid anti-inflammatory drugs (NSAID)and/or corticosteroids at the beginning of the disease. Twenty percent ofthe patients reached remission with corticosteroid or disease-modifyinganti-rheumatic drugs (DMARDs) however the rest of the patients needed atleast one biologic agent. Anakinra was the most common first-line biologictreatment choice (n=45). Fourteen (18,7%) of the patients had polyarticularjoint involvement during the disease course, and 5 of them achieved remissionwith tocilizumab.Systemic JIA is an important disease with high risk of morbidity and mortality.As our center is one of the most important tertiary referral rheumatologycenters in the country, we had a high MAS incidence. Eighty percent of thepatients achieved remission with a biological agent. Anti-IL1 drugs are mostlypreferred for ongoing systemic inflammation. Anti-IL-6 agents are veryefficient in patients with a polyarticular course.

PDF

___

1. Petty RE, Southwood TR, Manners P, et al; International League of Associations for Rheumatology International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-392
2. Shenoi S, Horneff G, Cidon M, et al. The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. Clin Exp Rheumatol 2018; 36: 920-928.
3. Singh-Grewal D, Schneider R, Bayer N, Feldman BM Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features. Arthritis Rheum 2006; 54: 1595-1601.
4. Lovell DJ, Passo M, Giannini E, Brunner H. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 2001; 28: 220.
5. Ravelli A, Minoia F, Davi S, et al; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 2016; 75: 481-489.
6. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N; Childhood Arthritis Rheumatology Research Alliance, Pediatric Rheumatology. Collaborative Study Group; Paediatric Rheumatology International Trials Organizsation. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis CareRes (Hoboken) 2011; 63: 929- 936.
7. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007; 34: 1133-1138.
8. Boom V, Anton J, Lahdenne P, et al. Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2015; 13: 55.
9. Minoia F, Davi S, Horne A, et al; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol 2014; 66: 3160-3169.
10. Sura A, Failing C, Sturza J, Stannard J, Riebschleger M. Patient characteristics associated with response to NSAID monotherapy in children with systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J 2018; 16: 2.
11. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum 2013; 65: 2499-2512.
12. Schneider R, Lang BA, Reilly BJ, et al. Prognostic indicators of joint destruction in systemic-onset juvenile rheumatoid arthritis. J Pediatr 1992; 120(2 Pt 1): 200-205.